PP_1170x120_10-25-21

Visante analysis

Visante: Stifling competition by drug manufacturers leads to high insulin prices

Visante: Stifling competition by drug manufacturers leads to high insulin prices

WASHINGTON — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to a new Visante analysis: “Insulins: Managing Costs with Increasing Manufacturer Prices.”  The Visante analysis finds that insulin list prices escalated over the past 5-10 years largely due to limited competition caused by an

Adheris Health